Benito José M, López Mariola, Martín Juan C, Lozano Sara, Martínez Pilar, González-Lahoz Juan, Soriano Vincent
Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid 28035, Spain.
AIDS Res Hum Retroviruses. 2002 Dec 10;18(18):1379-88. doi: 10.1089/088922202320935456.
The mechanism of CD4(+) T cell depletion seen in HIV infection is largely mediated by increased apoptosis of these cells. The benefit of protease inhibitor (PI)-based antiretroviral therapy to CD4(+) T cell recovery seems to involve more than its antiviral activity, and a direct antiapoptotic effect of PIs has been proposed to explain it. To test this hypothesis we have analyzed directly, ex vivo, the effects of two different highly active antiretroviral therapy (HAART) regimens on the levels of activation and apoptosis of T lymphocytes. A total of 126 subjects (43 receiving PIs, 35 receiving NNRTIs, 27 untreated HIV carriers, and 21 uninfected control subjects) was included in the study. Apoptosis was measured in blood lymphocytes by flow cytometry, using annexin V labeling. A broad panel of monoclonal antibodies was used to characterize the different CD4(+) and CD8(+) lymphocyte subsets. Apoptosis was significantly increased in HIV-untreated subjects, whereas apoptosis levels did not differ when comparing HIV-positive subjects undergoing HAART and uninfected control subjects. Likewise, markers of activation were elevated in HIV-positive untreated patients, and declined in subjects receiving treatment. However, activated-memory CD8(+) T cells remained significantly higher in treated patients with respect to uninfected control subjects. No differences in the level of apoptosis or in immune activation markers were recognized when comparing subjects receiving PIs and those receiving NNRTIs. Antiretroviral therapy reduces apoptosis of CD4(+) and CD8(+) lymphocytes to normal levels without differences when comparing subjects receiving PI and NNRTI triple combinations. Despite complete suppression of viral replication, activated memory CD8(+) T cells remain significantly elevated in subjects receiving HAART, suggesting the persistence of residual HIV replication. If PIs provide a positive effect on CD4(+) counts beyond an antiviral effect, mechanisms other than apoptosis should be involved.
在HIV感染中所见到的CD4(+) T细胞耗竭机制,很大程度上是由这些细胞凋亡增加所介导的。基于蛋白酶抑制剂(PI)的抗逆转录病毒疗法对CD4(+) T细胞恢复的益处似乎不仅仅涉及其抗病毒活性,并且有人提出PI的直接抗凋亡作用来解释这一点。为了验证这一假设,我们直接在体外分析了两种不同的高效抗逆转录病毒疗法(HAART)方案对T淋巴细胞活化水平和凋亡的影响。该研究共纳入了126名受试者(43名接受PI治疗、35名接受非核苷类逆转录酶抑制剂(NNRTI)治疗、27名未治疗的HIV携带者以及21名未感染的对照受试者)。通过使用膜联蛋白V标记,采用流式细胞术检测血液淋巴细胞中的凋亡情况。使用一组广泛的单克隆抗体来表征不同的CD4(+)和CD8(+)淋巴细胞亚群。未接受治疗的HIV受试者的凋亡显著增加,而在比较接受HAART的HIV阳性受试者和未感染的对照受试者时,凋亡水平并无差异。同样,HIV阳性未治疗患者的活化标志物升高,而接受治疗的受试者中该标志物下降。然而,与未感染的对照受试者相比,接受治疗患者的活化记忆CD8(+) T细胞仍显著更高。在比较接受PI治疗的受试者和接受NNRTI治疗的受试者时,未发现凋亡水平或免疫活化标志物存在差异。抗逆转录病毒疗法可将CD4(+)和CD8(+)淋巴细胞的凋亡降低至正常水平,在比较接受PI和NNRTI三联组合的受试者时无差异。尽管病毒复制被完全抑制,但在接受HAART的受试者中,活化记忆CD8(+) T细胞仍显著升高,这表明存在残余HIV复制。如果PI对CD4(+)细胞计数除抗病毒作用外还有积极影响,那么应该涉及凋亡以外的机制。